Phase I-II

Tough times continue at PharmaNet

Tough times continue at PharmaNet

By Phil Taylor

Clinical research specialist PharmaNet Development Group reported a decline in both sales and earnings for the third quarter but has kept its guidance for the financial year at the same level, albeit excluding an as-yet unresolved impairment charge.

Follow us

Product Innovations